Clin Oncol | Volume 6, Issue 1 | Mini Review | Open Access

NLRP3 Inflammasome Enhances Tumor Growth

Bernhard Ryffel^*

Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, Orleans, France

^*Correspondance to: Bernhard Ryffel 

Abstract

Tumor cell derived danger signals known as DAMPs activate the NLRP3 inflammasome leading to IL-1β/IL-18 production conferring a pro-inflammatory environment. The inflammatory tumor environment enhances the tumor progression and metastasis. The NLRP3 inflammasome or IL-1/IL-18 represents promising therapeutic targets in cancer therapy, which is discussed in this
review. Alternative targets such TLRs and cGAS/STING dependent immune regulators need to be considered. The metabolome and microbiome of the host are additional factors contributing to a successful chemo- and immunotherapy.

Citation:

Ryffel B. NLRP3 Inflammasome Enhances Tumor Growth. Clin Oncol. 2021;6:1874..